Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how well JNJ-95597528 works compared to a placebo in adults with moderate to severe asthma that is not adequately controlled. This Phase 2b trial aims to assess the treatments effects on reducing asthma exacerbations and improving lung function, focusing on participants who have been on stable inhaled corticosteroid and additional asthma controller medications. Participants will be randomly assigned to one of four groups three different dosing schedules of JNJ-95597528 or a matching placebo. The study drug and placebo are given via subcutaneous injection at specific weeks 0, 2, 12, 24, and 36, depending on the group. The trial is double-blind and placebo-controlled to compare safety and efficacy. During the study, participants will be monitored through regular visits up to 48 weeks to measure asthma exacerbations, lung function tests such as forced expiratory volume, exhaled nitric oxide levels, and asthma control questionnaires. Safety will be assessed by tracking adverse events up to 90 weeks. The study involves multiple scheduled doses and ongoing assessments to evaluate treatment response and safety over time.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the study drug Seltorexant compared with a placebo in adults and elderly participants with major depressive disorder MDD, a common mood disorder marked by persistent sadness and loss of interest. This Phase 3 study includes a double-blind treatment phase to measure improvement in depressive symptoms specifically in participants with moderate-to-severe insomnia symptoms. The study also aims to assess long-term safety and tolerability of Seltorexant in an open-label treatment phase. During the double-blind phase, participants will take either a Seltorexant tablet or a matching placebo once daily for 42 days. Those who qualify for the open-label phase will continue taking Seltorexant daily for up to 6 months. The study compares the two groups to understand how well Seltorexant works alone in treating MDD. Participants will undergo clinical assessments including depression rating scales, sleep disturbance questionnaires, and safety evaluations such as vital signs, laboratory tests, electrocardiograms, and suicidality ratings. Researchers will also monitor withdrawal symptoms and sexual functioning during the open-label phase. The total participation duration may extend over several months to evaluate both efficacy and long-term safety outcomes.